美国 · 新闻 · New York Post
‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA…
在 New York Post 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (nypost.com)
